A61K36/537

COMPOSITION FOR ANTI-OXIDATION AND ANTI-INFLAMMATION COMPRISING SALVIA PLEBEIA R BR EXTRACT AND CENTELLA ASIATICA EXTRACT
20230059068 · 2023-02-23 ·

The present invention relates to a composition for anti-oxidation and anti-inflammation, comprising a Salvia plebeia R. BR. extract and a Centella asiatica extract as an active ingredient. The composition exhibits a radical scavenging ability, and has excellent antioxidant, anti-inflammatory and anti-itching effects by significantly inhibiting inflammation and itch-inducing factors at gene and protein levels, and thus can be advantageously used as a cosmetic composition for anti-oxidation and anti-inflammation.

COMPOSITION FOR ANTI-OXIDATION AND ANTI-INFLAMMATION COMPRISING SALVIA PLEBEIA R BR EXTRACT AND CENTELLA ASIATICA EXTRACT
20230059068 · 2023-02-23 ·

The present invention relates to a composition for anti-oxidation and anti-inflammation, comprising a Salvia plebeia R. BR. extract and a Centella asiatica extract as an active ingredient. The composition exhibits a radical scavenging ability, and has excellent antioxidant, anti-inflammatory and anti-itching effects by significantly inhibiting inflammation and itch-inducing factors at gene and protein levels, and thus can be advantageously used as a cosmetic composition for anti-oxidation and anti-inflammation.

COMPOSITION FOR INHIBITING TUMOR PROLIFERATION COMPRISING SALVIA PLEBEIA EXTRACT AS EFFECTIVE COMPONENT

A composition according to an embodiment of the present disclosure can be used for inhibiting tumor proliferation and includes a Salvia plebeia extract as an effective component. It was found that, as a result of binding to PD-L1 present on a surface of cancer cell, Salvia plebeia extract blocks the interaction between cancer cell and PD-1 present on a surface of immune T cell to activate T cells and exhibit an inhibitory effect on tumor proliferation. It was also found that, according to co-culture of cells of colon cancer, breast cancer, or lung cancer with T cells, the group treated with Salvia plebeia extract shows higher effect of causing cancer cell death.

COMPOSITION FOR INHIBITING TUMOR PROLIFERATION COMPRISING SALVIA PLEBEIA EXTRACT AS EFFECTIVE COMPONENT

A composition according to an embodiment of the present disclosure can be used for inhibiting tumor proliferation and includes a Salvia plebeia extract as an effective component. It was found that, as a result of binding to PD-L1 present on a surface of cancer cell, Salvia plebeia extract blocks the interaction between cancer cell and PD-1 present on a surface of immune T cell to activate T cells and exhibit an inhibitory effect on tumor proliferation. It was also found that, according to co-culture of cells of colon cancer, breast cancer, or lung cancer with T cells, the group treated with Salvia plebeia extract shows higher effect of causing cancer cell death.

Stenting-Free Pharmaceutical Composition for Treatment of Cardiovascular and Cerebrovascular Disease
20220362307 · 2022-11-17 ·

The present disclosure provides a traditional Chinese medicine (TCM) composition for the treatment of cardiovascular and cerebrovascular diseases and use thereof, and belongs to the technical field of TCM. The composition for the treatment of cardiovascular and cerebrovascular diseases provided by the present disclosure includes the following raw materials: Radix Panacis Quinquefolii, Pheretima, Radix et Rhizoma Salviae Miltiorrhizae, Hirudo, Rhizoma Ligustici Chuanxiong, Rhizoma Gastrodiae, Fructus Crataegi, Stigma Croci, Herba Erigerontis, Semen Ginkgo, and Radix et Rhizoma Glycyrrhizae. The present disclosure treats the cardiovascular and cerebrovascular diseases through treatment based on syndrome differentiation and overall regulation in TCM; with less side effects, excellent efficacy, and fast acting, the present disclosure can achieve a stenting-free effect on the cardiovascular and cerebrovascular diseases.

Stenting-Free Pharmaceutical Composition for Treatment of Cardiovascular and Cerebrovascular Disease
20220362307 · 2022-11-17 ·

The present disclosure provides a traditional Chinese medicine (TCM) composition for the treatment of cardiovascular and cerebrovascular diseases and use thereof, and belongs to the technical field of TCM. The composition for the treatment of cardiovascular and cerebrovascular diseases provided by the present disclosure includes the following raw materials: Radix Panacis Quinquefolii, Pheretima, Radix et Rhizoma Salviae Miltiorrhizae, Hirudo, Rhizoma Ligustici Chuanxiong, Rhizoma Gastrodiae, Fructus Crataegi, Stigma Croci, Herba Erigerontis, Semen Ginkgo, and Radix et Rhizoma Glycyrrhizae. The present disclosure treats the cardiovascular and cerebrovascular diseases through treatment based on syndrome differentiation and overall regulation in TCM; with less side effects, excellent efficacy, and fast acting, the present disclosure can achieve a stenting-free effect on the cardiovascular and cerebrovascular diseases.

Stenting-Free Pharmaceutical Composition for Treatment of Cardiovascular and Cerebrovascular Disease
20220362307 · 2022-11-17 ·

The present disclosure provides a traditional Chinese medicine (TCM) composition for the treatment of cardiovascular and cerebrovascular diseases and use thereof, and belongs to the technical field of TCM. The composition for the treatment of cardiovascular and cerebrovascular diseases provided by the present disclosure includes the following raw materials: Radix Panacis Quinquefolii, Pheretima, Radix et Rhizoma Salviae Miltiorrhizae, Hirudo, Rhizoma Ligustici Chuanxiong, Rhizoma Gastrodiae, Fructus Crataegi, Stigma Croci, Herba Erigerontis, Semen Ginkgo, and Radix et Rhizoma Glycyrrhizae. The present disclosure treats the cardiovascular and cerebrovascular diseases through treatment based on syndrome differentiation and overall regulation in TCM; with less side effects, excellent efficacy, and fast acting, the present disclosure can achieve a stenting-free effect on the cardiovascular and cerebrovascular diseases.

Process for producing a Tan IIA nanoliposome system for foods and medical products
11583498 · 2023-02-21 · ·

The invention relates to a process for producing a Tan IIA nanoliposome system for foods and medical products, comprises: (i) preparing a dispersed phase by dissolving Tan IIA in ethanol in a Tan IIA weight:ethanol volume ratio of 8:10 by a stirrer at 300-500 rpm with heating to 40-60° C. within 4-8 hours; (ii) preparing a liposome carrier consisting of lecithin and olive oil in a ratio of 1:3 by weight by mixing in a constant temperature bath at 40-60° C. to ensure that lecithin is completely dissolved in the oil while stirring; (iii) adding the carrier to the dispersed phase in a ratio of 40:60 by weight, further heating the carrier and dispersed phase mixture to 40-60° C. and stirring at 800-1000 rpm within 1 to 2 hours; (iv) cooling the resulting mixture to 25° C. and pumping the cooled mixture, using an ultrasonic atomizer nozzle at 60 Hz (10-20 μm droplet size, 10 mL/min), into 1-1.5 L of distilled water (with the temperature of the distilled water at 25° C.) to obtain a liposome suspension-water mixture; (v) homogenizing the liposome suspension-water mixture by pumping through a high pressure homogenizer at 30 Mpa to obtain a Tan IIA nanoliposome system as a homogeneous and stable mixture with a confirmed particle size smaller than 200 nm.

Process for producing a Tan IIA nanoliposome system for foods and medical products
11583498 · 2023-02-21 · ·

The invention relates to a process for producing a Tan IIA nanoliposome system for foods and medical products, comprises: (i) preparing a dispersed phase by dissolving Tan IIA in ethanol in a Tan IIA weight:ethanol volume ratio of 8:10 by a stirrer at 300-500 rpm with heating to 40-60° C. within 4-8 hours; (ii) preparing a liposome carrier consisting of lecithin and olive oil in a ratio of 1:3 by weight by mixing in a constant temperature bath at 40-60° C. to ensure that lecithin is completely dissolved in the oil while stirring; (iii) adding the carrier to the dispersed phase in a ratio of 40:60 by weight, further heating the carrier and dispersed phase mixture to 40-60° C. and stirring at 800-1000 rpm within 1 to 2 hours; (iv) cooling the resulting mixture to 25° C. and pumping the cooled mixture, using an ultrasonic atomizer nozzle at 60 Hz (10-20 μm droplet size, 10 mL/min), into 1-1.5 L of distilled water (with the temperature of the distilled water at 25° C.) to obtain a liposome suspension-water mixture; (v) homogenizing the liposome suspension-water mixture by pumping through a high pressure homogenizer at 30 Mpa to obtain a Tan IIA nanoliposome system as a homogeneous and stable mixture with a confirmed particle size smaller than 200 nm.

EXTRACT OF AN HERBAL COMPOSITION AS ANTIMICROBIAL AND/OR ANTIBIOFILM AGENT
20220354919 · 2022-11-10 · ·

An extract of an herbal composition comprising at least two different dried plants useful as antimicrobial and/or antibiofilm agent in the treatment or prevention of microbial infections caused by bacteria, such as for example Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus or Staphylococcus, or by fungi, such as for example is herein described. It has been found that in such extract, the active ingredients exert their biological effects in a synergistic manner. The extract may constitute the active ingredient of a food supplement, a nutraceutical, pharmaceutical or cosmetic composition or a functional food or a food additive. A process for preparing said extract is also described here.